Table 2 Patient characteristics and details of treatment

Patient characteristics at start of MTX treatment ^a

Female (n)

25 (58,1%)

Age (y)

11 (6–14)

Height (cm)

145 (112–161)

Weight (kg)

35.3 (21.0-47.7)

BMI

16.6 (15.1–18.7)

BSA (m²)

1.19 (0.83–1.45)

Dose BSA-normalised (mg/m²)

11.3 (10.5–13.6)

Details of treatment ^a

Total MTX duration (days)

668 (461–896)

Baseline

Follow up

MTX dose (mg) ^a

12.5 (10–15)

12.5 (10–20)

Route of administration (n)

 - Subcutanous

 - Oral, tablet

 - Oral, inj. fluid

1 (2.3%)

37 (86.0%)

5 (11.6%)

1 (2.3%)

37 (86.0%)

5 (11.6%)

Comedication (n)

 - Adalimumab

 - Anakinra

 - Etanercept

 - Canakinumab

3 (7.0%)

1 (2.3%)

1 (2.3%)

0 (0.0%)

12 (27.9%)

1 (2.3%)

3 (70%)

1 (2.3%)